SUMC in the News (11/09/07)
Press releases
Silicon Valley couple pledge $27.5 million to Stanford Hospital for cutting-edge emergency care
Marc Andreessen and Laura Arrillaga-Andreessen have made a $27.5 million gift to Stanford Hospital & Clinics to build a state-of-the-art Emergency Department for both adults and children in the community. The facility will be called the Marc and Laura Andreessen Emergency Department.
Print media coverage
New York Times, 11/09/07
Bid for stem cell financing was late and lukewarm, organizers concede
This article discusses why a bid for stem cell financing in New Jersey failed to pass during the recent elections. Christopher Scott, director of the Program on Stem Cells in Society in the Stanford Center for Biomedical Ethics (SCBE), is quoted here.
Wall Street Journal, 11/09/07
Gift of the week: From flu to a $27.5 million donation (No online version available)
This brief item mentions the $27.5 million donation to Stanford Hospital from Marc Andreessen and Laura Arrillaga-Andreessen.
New Zealand Press Association, 11/09/07
Personalized stem cells seen as insurance for the future (No online version available)
A local company offers to create "personalized" stem cells from the spare embryos of fertility clinic clients on the chance that the cells may some day help a family member benefit from medical breakthroughs. David Magnus, director of the SCBE, provides comment in this article.
ScientificAmerican.com, 11/08/07
Govt. program a strain on U.S. emergency rooms: study
This Reuters article discusses a new study from Stanford and UCSF that found the U.S. government's Medicaid program for the poor may put more financial burden on overcrowded hospital emergency rooms than the nation's 47 million uninsured.
HealthDay News, 11/08/07
Vioxx ban tied to rise in serious GI trouble
A new study finds that rates of gastrointestinal events have risen significantly since cox-2 inhibitor medications, such as Vioxx and Bextra, were ordered off the market. Gurkipal Singh, a member of the adjunct clinical faculty and study author, is quoted in this article.
Reuters Health, 11/08/07
Arthritis drug effective in late-stage trial
Swiss drugmaker Roche Holding AG reported Wednesday that its experimental rheumatoid arthritis drug, Actemra, was effective in the second of five late-stage clinical trials. Mark Genovese, associate professor of immunology and rheumatology, provides comment in this article.
Office of Communication